Therapeutic Asset Ratings

3,272 results matching 1 filter

91,564 assets · 7,904 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Ipilimumab Glioma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Endometrium Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Endometrial Clear Cell Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Endometrial Undifferentiated Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Endometrial Endometrioid Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Endometrial Mixed Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Endometrial Mucinous Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Endometrial Transitional Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Endometrioid Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Undifferentiated Carcinoma Of Esophagus	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Extrahepatic Bile Duct Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Extramammary Paget Disease	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Fallopian Tube Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Fallopian Tube Transitional Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Fibromyxoid Tumor	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Gallbladder Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Gastric Squamous Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Undifferentiated Carcinoma Of Stomach	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Gastroesophageal Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Gestational Trophoblastic Neoplasm	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Lung Giant Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Cervical Clear Cell Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Infiltrating Bladder Urothelial Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Infiltrating Bladder Lymphoepithelioma-Like Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Nested Variant Infiltrating Bladder Urothelial Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)

Showing 1501 to 1525 of 3,272 assets

PreviousPage 61 of 131Next